Latest / The Diagnostics & Lab Testing Business Brief
The Diagnostics & Lab Testing Business Brief — Tuesday, November 3, 2026
The Diagnostics & Lab Testing Business Brief — Tuesday, November 3, 2026
The business behind the tests. Today's developments shaping the diagnostics industry.
Natera Signatera MRD test gains Medicare coverage in hepatocellular carcinoma: Medicare coverage through the CMS MolDX program includes serial Signatera testing in the surveillance setting for patients with early-stage HCC with no post-surgical evidence of disease; supported by a 125-patient real-world study in JCO Precision Oncology showing 83% sensitivity vs. 42% for AFP at 100% specificity, with a median lead time of 7.9 months ahead…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.